# Mesa Labs' first full-year guidance implies a softer second half than last year - Published: 2026-11-10 - Author: [CFO Drive](https://cfodrive.com/author/cfodrive-com.md) - Topics: [News](https://cfodrive.com/news.md) - About: [Mesa Laboratories, Inc.](https://www.mesalabs.com/) - Based on: [Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance](https://www.globenewswire.com/news-release/2026/11/09/3399034/30771/en/mesa-labs-announces-second-quarter-fiscal-year-2027-results-and-issues-first-full-year-guidance.html), GlobeNewswire, 2026-11-09 - Based on: [Mesa Labs Announces Fourth Quarter and Fiscal Year 2026 Results (Form 8-K, Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/724004/000072400426000039/ex_968718.htm), U.S. Securities and Exchange Commission, 2026-05-27 - Based on: [Mesa Labs first quarter fiscal year 2027 results (Form 8-K, Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/724004/000143774926026769/ex_1000989.htm), U.S. Securities and Exchange Commission, 2026-08-10 - Based on: [Mesa Laboratories Announces Restructuring and Savings Plan (Form 8-K, Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/724004/000143774926032499/ex_1025145.htm), U.S. Securities and Exchange Commission, 2026-10-13 - Source: https://cfodrive.com/news/mesa-labs-guidance-implies-softer-second-half/ - Publication: CFO Drive - Publisher: Connectively (Terkel, Inc.) - Editorial policy: https://cfodrive.com/editorial-policy/ Mesa Labs guidance for fiscal 2027, the first full-year outlook the Colorado quality-control and life-sciences tools maker has issued, came on November 9 with second-quarter results. Its chief executive calls the range conservative, and the numbers bear that out: they imply less adjusted EBITDA in the second half than a year ago. ## Key points - Mesa Laboratories (Nasdaq: MLAB) expects fiscal 2027 revenues of $250 million to $255 million and adjusted EBITDA of $66 million to $68 million, for the year ending March 31, 2027 ([release](https://www.globenewswire.com/news-release/2026/11/09/3399034/30771/en/mesa-labs-announces-second-quarter-fiscal-year-2027-results-and-issues-first-full-year-guidance.html)). - Second-quarter revenues rose 2.6% to $62.3 million and adjusted EBITDA rose 21.1% to $17.3 million, or 27.8% of revenues ([release](https://www.globenewswire.com/news-release/2026/11/09/3399034/30771/en/mesa-labs-announces-second-quarter-fiscal-year-2027-results-and-issues-first-full-year-guidance.html)). - The company repaid $11.4 million of debt in the quarter and says its Total Net Leverage Ratio fell to 1.75 ([release](https://www.globenewswire.com/news-release/2026/11/09/3399034/30771/en/mesa-labs-announces-second-quarter-fiscal-year-2027-results-and-issues-first-full-year-guidance.html)), from 2.11 at March 31 ([fiscal 2026 release](https://www.sec.gov/Archives/edgar/data/724004/000072400426000039/ex_968718.htm)). - On November 4 the board replaced a buyback authorized in 2005 with a new program to repurchase up to $40 million of stock through December 31, 2028 ([release](https://www.globenewswire.com/news-release/2026/11/09/3399034/30771/en/mesa-labs-announces-second-quarter-fiscal-year-2027-results-and-issues-first-full-year-guidance.html)). - Diluted earnings per share were $0.75, against $0.45 in the second quarter of fiscal 2026 ([release](https://www.globenewswire.com/news-release/2026/11/09/3399034/30771/en/mesa-labs-announces-second-quarter-fiscal-year-2027-results-and-issues-first-full-year-guidance.html)). ## What is Mesa Labs guidance for fiscal 2027? Mesa Labs guidance calls for flat to slightly higher sales and a modest rise in adjusted EBITDA. The company puts revenue growth at about 0% to 2% and adjusted EBITDA growth at about 5% to 8%, measured against the $62,969 thousand of adjusted EBITDA it reported for fiscal 2026. The range includes the net effect of the cost program announced in October and lower Clinical Genomics sales, and it leaves out restructuring charges. Mesa says it has not reconciled the EBITDA outlook to net income, citing items it cannot forecast such as taxes, currency effects, the timing of restructuring charges and any impairments. It also warns that growth will be uneven by quarter, and expects third-quarter revenues to be about flat with a year earlier. > We have built it conservatively, on a half-year of data under the changes we have made, because a number that our shareholders can count on is worth more than one that flatters a quarter — Dr. Siddhartha Kadia, President and CEO, Mesa Laboratories The outlook keeps a promise. Kadia joined on April 13 ([fiscal 2026 release](https://www.sec.gov/Archives/edgar/data/724004/000072400426000039/ex_968718.htm)), and in the [first-quarter release](https://www.sec.gov/Archives/edgar/data/724004/000143774926026769/ex_1000989.htm) in August he said he would give full-year guidance alongside first-half results in November. ## What does the guidance imply for the second half? Subtracting the first half from the full-year range, Mesa is guiding to second-half adjusted EBITDA of $33.2 million to $35.2 million, below the $35.8 million it earned in the same months of fiscal 2026, by our arithmetic from the [release](https://www.globenewswire.com/news-release/2026/11/09/3399034/30771/en/mesa-labs-announces-second-quarter-fiscal-year-2027-results-and-issues-first-full-year-guidance.html). That is after first-half adjusted EBITDA rose to $32.8 million from $27.2 million. | Adjusted EBITDA, $ thousands (non-GAAP) | First half (April to September) | Second half (October to March) | Full year | | --- | --- | --- | --- | | Fiscal 2026, reported ([release](https://www.globenewswire.com/news-release/2026/11/09/3399034/30771/en/mesa-labs-announces-second-quarter-fiscal-year-2027-results-and-issues-first-full-year-guidance.html)) | 27,160 | 35,809 | 62,969 | | Fiscal 2027, first half reported plus guidance (second half derived from the [release](https://www.globenewswire.com/news-release/2026/11/09/3399034/30771/en/mesa-labs-announces-second-quarter-fiscal-year-2027-results-and-issues-first-full-year-guidance.html)) | 32,836 | 33,164 to 35,164 | 66,000 to 68,000 | Revenue tells a similar story. Fiscal 2026 revenues were $249.1 million ([fiscal 2026 release](https://www.sec.gov/Archives/edgar/data/724004/000072400426000039/ex_968718.htm)), so the new range implies second-half revenues of $127.5 million to $132.5 million against $128.9 million a year earlier, a change of about minus 1% to plus 3%, by our arithmetic. The implied second-half margin, about 26.0% to 26.5%, sits below last year's 27.8% for the same half ([release](https://www.globenewswire.com/news-release/2026/11/09/3399034/30771/en/mesa-labs-announces-second-quarter-fiscal-year-2027-results-and-issues-first-full-year-guidance.html)). The release does not explain the second half directly. It says the guidance reflects the savings plan net of the reinvestment it funds, and lower Clinical Genomics sales, which Mesa expects to fall through the rest of this year and into fiscal 2028 as it drops lower-margin products and accounts. Outside Clinical Genomics, Mesa says it expects revenues to keep growing, so the flat revenue outlook rests largely on the division it is shrinking. ## How is Mesa cutting costs and allocating capital? Mesa is shrinking its weakest division, paying down debt and adding a buyback. Its [October 13 announcement](https://www.sec.gov/Archives/edgar/data/724004/000143774926032499/ex_1025145.htm) set out a plan to cut about 40 positions, roughly 6% of staff, mostly in Clinical Genomics and corporate functions, and to save about $9.3 million a year before reinvesting about $4.3 million. The company expects pre-tax restructuring charges of $2.6 million to $3.4 million, mainly in the second half of fiscal 2027, and will leave its Hamburg, Germany facility when the lease ends in February 2027 ([release](https://www.globenewswire.com/news-release/2026/11/09/3399034/30771/en/mesa-labs-announces-second-quarter-fiscal-year-2027-results-and-issues-first-full-year-guidance.html)). The company lists its capital priorities as reinvesting in its own businesses, keeping the balance sheet strong, then bringing distributors in-house and making small tuck-in acquisitions in its Quality Control businesses. It says the buyback gives it room to repurchase shares opportunistically while it keeps reducing debt, funded from cash on hand and operating cash flow. Cash stood at $22.3 million on September 30 ([release](https://www.globenewswire.com/news-release/2026/11/09/3399034/30771/en/mesa-labs-announces-second-quarter-fiscal-year-2027-results-and-issues-first-full-year-guidance.html)). By division, Sterilization and Disinfection Control grew 14.6%, which Mesa says largely reflects production problems that held back the year-ago quarter. Biopharmaceutical Development fell 8.2%, which the company blames on export-control processing delays for peptide hardware. Mesa also says a September FDA inspection of its Bozeman, Montana biological indicator plant closed with no Form 483 observations. ## What does the release leave out? The release gives no total debt figure, only the leverage ratio and the amount repaid, so the remaining borrowing cannot be sized from it. It does not say how fast Mesa plans to use the $40 million [authorization](https://www.globenewswire.com/news-release/2026/11/09/3399034/30771/en/mesa-labs-announces-second-quarter-fiscal-year-2027-results-and-issues-first-full-year-guidance.html), how far Clinical Genomics sales will fall, or when the export-control delays in Biopharmaceutical Development will clear. There is no GAAP earnings outlook, and the guidance does not split the second half by quarter beyond a roughly flat third quarter. ## What should CFOs take from Mesa's first guidance? Our analysis: Mesa has chosen to set a first number it can beat rather than one that extends its strong second quarter, and the arithmetic shows how much room that leaves: the range sits below last year's second half even as the first half grew. For finance leaders preparing their own first outlook, the trade-off between credibility and ambition is the one practitioners debate in [designing guidance for earnings calls](https://cfodrive.com/qa/designing-guidance-for-q4-earnings-calls/) and in [keeping forecasts credible without constantly resetting targets](https://cfodrive.com/qa/how-finance-leaders-keep-forecasts-credible-without-constantly-resetting-targets/). Pairing a buyback with continued debt reduction is a sequencing call of the kind covered in [capital allocation calls finance leaders can defend under pressure](https://cfodrive.com/qa/capital-allocation-calls-finance-leaders-can-defend-under-pressure/). ## Frequently asked questions ### Has Mesa Labs given guidance before? No. The company describes its November 9, 2026 outlook as its first full-year guidance. In its earlier results releases this year, Mesa said guidance would come with first-half results. ### What is Mesa Labs' fiscal 2027 revenue guidance? Mesa expects revenues of $250 million to $255 million for the fiscal year ending March 31, 2027, about 0% to 2% growth, according to its [November 9 release](https://www.globenewswire.com/news-release/2026/11/09/3399034/30771/en/mesa-labs-announces-second-quarter-fiscal-year-2027-results-and-issues-first-full-year-guidance.html). It expects adjusted EBITDA of $66 million to $68 million. ### Why does Mesa expect Clinical Genomics revenue to fall? Mesa is refocusing the division on pharmacogenomics, oncology and high-utilization accounts and is managing it for profit rather than scale. It expects revenue to decline as it moves away from lower-margin products and accounts. ### How large is Mesa Labs' new share repurchase program? The board authorized buybacks of up to $40 million of common stock, expiring December 31, 2028, according to the company's [November 9 release](https://www.globenewswire.com/news-release/2026/11/09/3399034/30771/en/mesa-labs-announces-second-quarter-fiscal-year-2027-results-and-issues-first-full-year-guidance.html). The program replaces one authorized in 2005 and does not oblige Mesa to buy any set amount. ## Sources - [Press release from Mesa Laboratories via GlobeNewswire, November 9, 2026: second quarter fiscal 2027 results and first full-year guidance](https://www.globenewswire.com/news-release/2026/11/09/3399034/30771/en/mesa-labs-announces-second-quarter-fiscal-year-2027-results-and-issues-first-full-year-guidance.html) - [Mesa Laboratories fourth quarter and fiscal 2026 results, filed with the SEC on May 27, 2026](https://www.sec.gov/Archives/edgar/data/724004/000072400426000039/ex_968718.htm) - [Mesa Laboratories first quarter fiscal 2027 results, filed with the SEC on August 10, 2026](https://www.sec.gov/Archives/edgar/data/724004/000143774926026769/ex_1000989.htm) - [Mesa Laboratories restructuring and savings plan announcement, filed with the SEC on October 13, 2026](https://www.sec.gov/Archives/edgar/data/724004/000143774926032499/ex_1025145.htm)